This article is more than 5 years old. Information may no longer be current.

Antiepilepsy drug associated with visual field defects

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The antiepilepsy drug vigabatrin may cause visual defects in patients, according to a retrospective study.

Vigabatrin is currently pending regulatory approval in the United States. Previous studies have linked the drug to visual field defects.

Francisco Ascaso and colleagues at the University Clinic Hospital in Zaragoza, Spain, reviewed the charts of 15 children receiving vigabatrin for treatment of epilepsy. The patients, ranging in age from 6 to 18, underwent visual field examinations with the Humphrey Field Analyzer.

Three patients showed visual field defects, consisting of localized, bilateral and relatively symmetrical nasal field loss. There was relative preservation of the temporal field within the central 30· area.

The current study is published in Documenta Ophthalmologica. For more on the subject, click here.